Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) ...
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 19, 2026 after market ...
The notes will be senior, unsecured obligations of Indivior and will accrue interest at a rate of 0.625% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, ...
On November 13, 2025, the Company announced additional 52-week follow-up data from the RESOLVE trial in eosinophilic esophagitis (“EoE”) demonstrating consistent results after dosing with EP-104GI.
NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury ...
DigitalOptometrics (DO), the leading provider of tele-optometry and remote ophthalmic care solutions, today announced the next major evolution of its platform at Vision Expo East, further advancing ...
No published clinical trial appears to have evaluated GlycoPezil as a proprietary formula. If you've been researching blood sugar support supplements lately, GlycoPezil is likely one of the names ...
Net revenue was $18.8 million, compared to $14.2 million for the year ended December 31, 2024, up 33% Net income was $1.2 million, compared with $74,000 in 2024 Adjusted EBITDA was $1.6 million, ...
Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including ...
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an ...
In October 2025, Tonix presented an update at the Japan Society for Transplantation annual congress, highlighting Phase 1 safety and pharmacokinetic and pharmacodynamic results and outlining next ...
The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results